• CLC comments on FDA Biosimilars Action Plan
  (September 21, 2018)

• Cancer Leadership Council Urges Establishment of Oncology Center of Excellence
  (June 22, 2016)

• CLC Comments on 21st Century Cures Effort
  (March 27, 2015)

• CLC comments on FDA plan for sharing masked and de-identified data
  (October 31, 2013)

• CLC Comments on CY 2014 Physician Fee Schedule Update
  (September 6, 2013)

• CLC Comments on FDA Guidance Document on Expedited Programs for Serious Conditions
  (August 26, 2013)

• CLC offers comments on House Energy & Commerce Committee Track and Trace Legislation
  (May 14, 2013)

• CLC comments on FDA plan for implementation of new benefit and risk assessment process
  (May 7, 2013)

• CLC offers advice to HELP Committee on legislation to establish a drug distribution security system
  (April 26, 2013)

• CLC Provides FDA Guidance on Drug Shortages Strategic Plan
  (March 14, 2013)

• Cancer Leadership Council comments on proposal for an alternative approval pathway for certain diseases
  (March 1, 2013)

• CLC Urges Release of Draft Guidance on Laboratory-Developed Tests
  (November 21, 2012)

• CLC Urges Strong Drug Shortage Provisions in User Fee Legislation
  (June 15, 2012)

• CLC Urges Adoption of Strong Pediatric Research Provisions in User Fee Legislation
  (June 15, 2012)

• CLC Urges FDA to Finalize Regulations on Expanded Access
  (June 25, 2008)

• CLC Recommends Revisions of Proposed Rules for Advisory Committee Conflicts of Interest
  (May 29, 2007)

• CLC Urges Favorable Consideration of Citizen Petition on Expanded Access Programs
  (June 12, 2006)

• CLC Recommends the Appointment of a Permanent FDA Commissioner
  (November 18, 2005)

• CLC Comments on FDA Guidance on Cancer Endpoints
  (June 3, 2005)

• CLC Applauds FDA Guidance on Central IRB Review
  (May 27, 2005)

• CLC Recommends Prompt Appointment of Director of Oncology Products Office (November 5, 2004)

FDA Review of Oral Cancer Agents

• CLC Recommends Changes in FDA Review of Cancer Therapies
  (February 24, 2003)
  
  
• CLC Endorses Dr. Richard Pazdur for FDA Commissioner
  (July 12, 2001)
  
  
• Letter to Rep. Allen Re: FDA Approval Process
  (July 10, 2001

• Letter to Tommy Thompson Applauding Expeditious Approval of New Cancer Therapy
  (May 31, 2001)
  
  
• Letter to Janet Woodcock Voicing Concerns Regarding FDA Review of Oral Cancer Agents
  (November 15, 2000)

Drug Importation Provision of FY2001 Agriculture Appropriations Bill

• Letter to Agriculture Appropriations Conferees and Other Key Members of Congress Objecting to Drug Importation Provisions
  (November 15, 2000)

Complementary and Alternative Medicine

• Letter to Representative Dan Burton Regarding Government Reform Committee Deliberations on Integrative Medicine
  (June 21, 2000)

Pediatric Exclusivity

• Comments on Implementation of Pediatric Exclusivity Provisions of the Food and Drug Administration Modernization Act
  (June 5, 2000)

Hatch-Waxman Reform

• Letter to Senator Orrin G. Hatch Recommending Principles for Revision of Hatch-Waxman Law
  (February 7, 2000)

About CLC  |  What's New  |  Policy Issues  |  Participants' Login
Home  |  Sitemap  |  Contact Info

Copyright © 2001-2002 Cancer Leadership Council. All rights reserved.
Please send comments and suggestions to webmaster@cancerleadership.org.